S

SYLENTIS

31 employees

SYLENTIS, biotech company focused on the development of new ophthalmic drugs and novel therapies based on RNAi (gene silencig) technology.

Basic info

Industry

biotechnology research

Sectors

Target Therapies
Glaucoma
Biotechnology
RNAi
Biotech
Gene Sinlencing
Research
Licensing
Biotecología
R&D
Dry eye syndrome
Experimental drugs
RNAi Clinical Trials
Ophtalmology
Production
Rational Design
eyes diseases
Ophthalmology
Drug Discovey
Bioinformatics
siRNA RNAi Drugs
Pharmaceuticals

Date founded

2006

FAQ